test

A Phase I/II Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients with Advanced Cancers

Conditions

Lymphoid Leukemia

What is the purpose of this trial?

This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Isis Pharmaceuticals
Dates:
02/12/2014
Last Updated:
Study HIC#:
1311013051